http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5962454-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_746d8243701ae4271b74368451625bee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 |
| filingDate | 1996-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81c90402b009bfea96b774d08649145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3713841fd8be75cfba3cc27e4b26901f |
| publicationDate | 1999-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-5962454-A |
| titleOfInvention | Neovascularization inhibitor |
| abstract | PCT No. PCT/JP96/01069 Sec. 371 Date Oct. 20, 1997 Sec. 102(e) Date Oct. 20, 1997 PCT Filed Apr. 19, 1996 PCT Pub. No. WO96/32945 PCT Pub. Date Oct. 24, 1996The invention relates to a neovascularization inhibitor composition comprising a compound of the following general formula [I] or a salt thereof, or a solvate thereof, as an active ingredient, wherein R1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; R2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; or R1 and R2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR1R2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted. |
| priorityDate | 1995-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 207.